Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 388

1.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2018 Dec 18. pii: S1083-8791(18)30890-5. doi: 10.1016/j.bbmt.2018.12.068. [Epub ahead of print]

PMID:
30576834
2.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N.

Leukemia. 2018 Dec 20. doi: 10.1038/s41375-018-0302-y. [Epub ahead of print]

PMID:
30573777
3.

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, Risitano AM; Severe Aplastic Anaemia Working Party of the EBMT.

Am J Hematol. 2019 Jan;94(1):80-86. doi: 10.1002/ajh.25314. Epub 2018 Nov 25.

PMID:
30328134
4.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2018 Sep 5. pii: S1083-8791(18)30531-7. doi: 10.1016/j.bbmt.2018.08.029. [Epub ahead of print]

PMID:
30194027
5.

Somatic Mutations in Aplastic Anemia.

Mufti GJ, Marsh JCW.

Hematol Oncol Clin North Am. 2018 Aug;32(4):595-607. doi: 10.1016/j.hoc.2018.03.002. Epub 2018 Jun 5. Review.

PMID:
30047413
6.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.

Chitre S, Stölzel F, Cuthill K, Streetly M, Graham C, Dill C, Mohamedali A, Smith A, Schetelig J, Altmann H, Bornhäuser M, Mufti GJ.

Leukemia. 2018 Sep;32(9):2020-2024. doi: 10.1038/s41375-018-0208-8. Epub 2018 Jul 19. No abstract available.

PMID:
30026569
7.

Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2224-2232. doi: 10.1016/j.bbmt.2018.07.007. Epub 2018 Aug 7.

PMID:
30009981
8.

Diagnostic algorithm for lower-risk myelodysplastic syndromes.

Mufti GJ, McLornan DP, van de Loosdrecht AA, Germing U, Hasserjian RP.

Leukemia. 2018 Aug;32(8):1679-1696. doi: 10.1038/s41375-018-0173-2. Epub 2018 Jun 26. Review.

PMID:
29946191
9.

Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.

Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ.

Eur J Haematol. 2018 Oct;101(4):466-474. doi: 10.1111/ejh.13085.

PMID:
29714032
10.

miR-181c-BRK1 axis plays a key role in actin cytoskeleton-dependent T cell function.

Lim SP, Ioannou N, Ramsay AG, Darling D, Gäken J, Mufti GJ.

J Leukoc Biol. 2018 May;103(5):855-866. doi: 10.1002/JLB.1A0817-325RR. Epub 2018 Apr 14.

PMID:
29656550
11.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Marsh JCW, Gutierrez-Rodrigues F, Cooper J, Jiang J, Gandhi S, Kajigaya S, Feng X, Ibanez MDPF, Donaires FS, Lopes da Silva JP, Li Z, Das S, Ibanez M, Smith AE, Lea N, Best S, Ireland R, Kulasekararaj AG, McLornan DP, Pagliuca A, Callebaut I, Young NS, Calado RT, Townsley DM, Mufti GJ.

Blood Adv. 2018 Jan 4;2(1):36-48. doi: 10.1182/bloodadvances.2017008110. eCollection 2018 Jan 9.

12.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.

PMID:
29196078
13.

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Alimam S, McLornan DP, Jiang J, Radia D, Mufti GJ, Harrison CN.

Haematologica. 2018 Jun;103(6):e234-e236. doi: 10.3324/haematol.2017.180851. Epub 2017 Nov 30. No abstract available.

14.

Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men.

Belsey SL, Ireland R, Lang K, Kizilors A, Ho A, Mufti GJ, Bisquera A, De Lavallade H, Flanagan RJ.

Ther Drug Monit. 2017 Oct;39(5):499-504. doi: 10.1097/FTD.0000000000000440.

PMID:
28767619
15.

Pre-symptomatic (Baseline) computed tomography predicts invasive pulmonary aspergillosis in high-risk adult haemato-oncology patients.

Ceesay MM, Desai SR, Cleverley J, Berry L, Smith M, Wade J, Mufti GJ, Pagliuca A.

Br J Haematol. 2018 Sep;182(5):723-727. doi: 10.1111/bjh.14858. Epub 2017 Jul 24. No abstract available.

PMID:
28737208
16.

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE.

Cell Rep. 2017 Jul 18;20(3):572-585. doi: 10.1016/j.celrep.2017.06.067.

17.
18.

Preclinical modeling of myelodysplastic syndromes.

Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D.

Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

19.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N.

Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20.

PMID:
28319072
20.

FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity.

Gaymes TJ, Mohamedali A, Eiliazadeh AL, Darling D, Mufti GJ.

Cancer Res. 2017 Apr 1;77(7):1697-1708. doi: 10.1158/0008-5472.CAN-16-1678. Epub 2017 Jan 20.

21.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17. Review.

22.

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.

Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, Sen M, Best S, Lea N, Rice C, Pagliuca A, Mufti GJ, Marsh JCW, Barber LD.

Biol Blood Marrow Transplant. 2017 Feb;23(2):293-299. doi: 10.1016/j.bbmt.2016.11.003. Epub 2016 Nov 2.

23.

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

Rouault-Pierre K, Smith AE, Mian SA, Pizzitola I, Kulasekararaj AG, Mufti GJ, Bonnet D.

Haematologica. 2017 Jan;102(1):e7-e10. doi: 10.3324/haematol.2016.152520. Epub 2016 Oct 6. No abstract available.

24.

Spontaneous myonecrosis in chronic myeloid leukaemia.

Renshaw H, Gandhi S, Shah A, Ireland R, Marsh JC, Mufti GJ.

Br J Haematol. 2016 Oct;175(2):190. doi: 10.1111/bjh.14278. Epub 2016 Aug 12. No abstract available.

PMID:
27514928
25.

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis.

Alkhatabi HA, McLornan DP, Kulasekararaj AG, Malik F, Seidl T, Darling D, Gaken J, Mufti GJ.

Oncotarget. 2016 Jul 26;7(30):47875-47890. doi: 10.18632/oncotarget.10293.

26.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P.

J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.

PMID:
27354480
27.

Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation.

Ceesay MM, Kordasti S, Rufaie E, Lea N, Smith M, Wade J, Douiri A, Mufti GJ, Pagliuca A.

J Infect. 2016 Sep;73(3):280-8. doi: 10.1016/j.jinf.2016.04.040. Epub 2016 Jun 22.

PMID:
27343564
28.

Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment.

Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, McLornan D, Diggins KE, Kulasekararaj A, Benfatto C, Feng X, Smith A, Mian SA, Melchiotti R, de Rinaldis E, Ellis R, Petrov N, Povoleri GA, Chung SS, Thomas NS, Farzaneh F, Irish JM, Heck S, Young NS, Marsh JC, Mufti GJ.

Blood. 2016 Sep 1;128(9):1193-205. doi: 10.1182/blood-2016-03-703702. Epub 2016 Jun 8.

29.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socié G, Bruno B, Meijer E, Mufti GJ, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1615-1620. doi: 10.1016/j.bbmt.2016.05.026. Epub 2016 Jun 3.

30.

Clinical significance of acquired somatic mutations in aplastic anaemia.

Marsh JC, Mufti GJ.

Int J Hematol. 2016 Aug;104(2):159-67. doi: 10.1007/s12185-016-1972-8. Epub 2016 Mar 18. Review.

PMID:
27084249
31.

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome.

Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, Seidl T, Rye KP, Hagen KM, Kulasekararaj A, Bruserud Ø, Mufti GJ.

Oncoimmunology. 2015 Jun 24;5(2):e1062208. eCollection 2016 Feb.

32.

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E.

Oncotarget. 2016 Apr 19;7(16):22103-15. doi: 10.18632/oncotarget.7899.

33.

Autoimmune diseases and myelodysplastic syndromes.

Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK.

Am J Hematol. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4.

34.

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.

Guerenne L, Beurlet S, Said M, Gorombei P, Le Pogam C, Guidez F, de la Grange P, Omidvar N, Vanneaux V, Mills K, Mufti GJ, Sarda-Mantel L, Noguera ME, Pla M, Fenaux P, Padua RA, Chomienne C, Krief P.

J Hematol Oncol. 2016 Jan 27;9:5. doi: 10.1186/s13045-016-0235-8.

35.

CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.

Smith AE, Kulasekararaj AG, Jiang J, Mian S, Mohamedali A, Gaken J, Ireland R, Czepulkowski B, Best S, Mufti GJ.

Lancet Haematol. 2015 May;2(5):e212-21. doi: 10.1016/S2352-3026(15)00050-2. Epub 2015 May 6.

PMID:
26688096
36.

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.

Mian SA, Rouault-Pierre K, Smith AE, Seidl T, Pizzitola I, Kizilors A, Kulasekararaj AG, Bonnet D, Mufti GJ.

Nat Commun. 2015 Dec 8;6:10004. doi: 10.1038/ncomms10004.

37.

Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.

Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA.

PLoS One. 2015 Oct 22;10(10):e0140483. doi: 10.1371/journal.pone.0140483. eCollection 2015.

38.

Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

Mufti GJ, Kulasekararaj AG, Marsh JC.

N Engl J Med. 2015 Oct 22;373(17):1674-5. doi: 10.1056/NEJMc1509703. No abstract available.

PMID:
26488705
39.

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.

Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, McLornan DP, Mufti GJ.

Br J Haematol. 2015 Oct;171(1):60-73. doi: 10.1111/bjh.13519. Epub 2015 Jun 15.

PMID:
26075866
40.

Chronic relapsing remitting Sweet syndrome--a harbinger of myelodysplastic syndrome.

Kulasekararaj AG, Kordasti S, Basu T, Salisbury JR, Mufti GJ, du Vivier AW.

Br J Haematol. 2015 Sep;170(5):649-56. doi: 10.1111/bjh.13485. Epub 2015 May 12.

PMID:
25962438
41.

High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).

Mohamedali AM, Gäken J, Ahmed M, Malik F, Smith AE, Best S, Mian S, Gaymes T, Ireland R, Kulasekararaj AG, Mufti GJ.

Leukemia. 2015 Sep;29(9):1928-38. doi: 10.1038/leu.2015.110. Epub 2015 May 6.

PMID:
25943179
42.

Life coaching following haematopoietic stem cell transplantation: a mixed-method investigation of feasibility and acceptability.

Kenyon M, Young F, Mufti GJ, Pagliuca A, Lim Z, Ream E.

Eur J Cancer Care (Engl). 2015 Jul;24(4):531-41. doi: 10.1111/ecc.12297. Epub 2015 Feb 25.

PMID:
25711722
43.

A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells.

Collin JF, Wells JW, Czepulkowski B, Lyne L, Duriez PJ, Banham AH, Mufti GJ, Guinn BA.

Genes Chromosomes Cancer. 2015 May;54(5):288-302. doi: 10.1002/gcc.22242. Epub 2015 Feb 23.

PMID:
25706801
44.

Applying synthetic lethality for the selective targeting of cancer.

McLornan DP, List A, Mufti GJ.

N Engl J Med. 2014 Oct 30;371(18):1725-35. doi: 10.1056/NEJMra1407390. Review. No abstract available.

PMID:
25354106
45.

Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.

Bart-Smith EE, Kordasti S, Kulasekararaj AG, Richardson D, Mufti GJ, Marsh JC.

AIDS. 2014 Nov 28;28(18):2786-8. doi: 10.1097/QAD.0000000000000504.

PMID:
25333665
46.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A.

Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6. doi: 10.1016/j.bbmt.2014.09.009. Epub 2014 Sep 28.

47.

Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes.

Bart-Smith E, Mufti GJ.

Curr Opin Oncol. 2014 Nov;26(6):642-9. doi: 10.1097/CCO.0000000000000137. Review.

PMID:
25208055
48.

A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients.

Ceesay MM, Desai SR, Berry L, Cleverley J, Kibbler CC, Pomplun S, Nicholson AG, Douiri A, Wade J, Smith M, Mufti GJ, Pagliuca A.

Br J Haematol. 2015 Jan;168(2):219-29. doi: 10.1111/bjh.13114. Epub 2014 Sep 1.

PMID:
25179933
49.

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.

Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, Yang AS, Fenaux P.

Leukemia. 2014 Dec;28(12):2418-21. doi: 10.1038/leu.2014.253. Epub 2014 Sep 2. No abstract available.

50.

Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.

Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S, Gaken J, Czepulkowski B, Marsh JC, Mufti GJ.

Blood. 2014 Oct 23;124(17):2698-704. doi: 10.1182/blood-2014-05-574889. Epub 2014 Aug 18.

Supplemental Content

Loading ...
Support Center